Page last updated: 2024-10-17

phosphonoacetic acid and Adenocarcinoma, Basal Cell

phosphonoacetic acid has been researched along with Adenocarcinoma, Basal Cell in 26 studies

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.

Research Excerpts

ExcerptRelevanceReference
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas."9.07A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."7.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."7.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas."5.07A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."3.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
" The extent of control of the EMT-6 mammary adenocarcinoma was determined using fractionated radiation (12 irradiations) over a 3-week period using the radiosensitizer 5-chloro-2'-deoxycytidine (CldC) and biomodulators of its metabolism: N-(Phosphonacetyl)-L-aspartate (PALA), tetrahydrouridine and 5-fluoro-2'-deoxycytidine (FdC)."3.69Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. ( Greer, S; Marion, HS; Schwade, J, 1995)
"To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma."3.69Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."3.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA."3.67Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985)
"Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)."3.67Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985)
"Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers."1.26Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19907 (26.92)18.7374
1990's16 (61.54)18.2507
2000's3 (11.54)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Johnston, PG1
Benson, AB1
Catalano, P1
Rao, MS1
O'Dwyer, PJ5
Allegra, CJ2
Whitehead, RP1
Benedetti, JK1
Abbruzzese, JL1
Ardalan, B3
Goodwin, JW1
Balcerzak, SP1
Samlowski, WE1
Lenz, HJ1
Macdonald, JS3
Rubin, J1
Schutt, AJ1
O'Connell, MJ1
Gertz, MA1
Moertel, CG1
Earhart, RH1
Elson, PJ1
Rosenthal, SN1
Hahn, RG1
Slayton, RE1
Natale, RB1
Yagoda, A1
Kelsen, DP1
Gralla, RJ1
Watson, RC1
Greer, S1
Schwade, J2
Marion, HS1
Redei, I1
Green, F1
Hoffman, JP1
Weiner, LM3
Scher, R1
Ucar, A1
Reddy, R1
Livingstone, AS1
Markoe, A1
Richman, SP3
Donofrio, K1
Grem, JL2
McAtee, N1
Steinberg, SM1
Hamilton, JM2
Murphy, RF1
Drake, J1
Chisena, T1
Balis, F1
Cysyk, R1
Arbuck, SG1
Hudes, GR1
Kitson, J1
Walczak, J3
Watts, P1
Litwin, S2
Yang, JL1
Fernandes, DJ1
Wheeler, KT1
Capizzi, RL1
Wadler, S1
Gleissner, B1
Hilgenfeld, RU1
Thiel, E1
Haynes, H1
Kaleya, R1
Rozenblit, A1
Kreuser, ED1
Ragnhammar, P1
Blomgren, H1
Martino, RL1
Fleming, TR2
Morrell, LM2
Köhne, CH2
Wilke, H2
Schöffski, P1
Schmoll, HJ2
Harstrick, A1
Hiddemann, W1
Preusser, P1
Strumberg, D1
Berns, T1
Seeber, S1
Yee, LK1
Schuler, B1
Chen, AP1
Chabuk, C1
Grollman, F1
Grabenc, M1
Takimoto, CH1
Tsuboi, KK1
Kwong, LK1
Kelsen, D1
Martin, DS2
Colofiore, J2
Sawyer, R1
Coit, D1
Rosvold, E1
Schilder, R1
DiFino, SM1
Flynn, PJ1
Banerjee, TK1
Heim, WJ1
Engstrom, PF1
Ozols, RF1
Kemeny, N2
Conti, JA1
Seiter, K1
Niedzwiecki, D1
Botet, J1
Martin, D1
Costa, P1
Wiseberg, J1
McCulloch, W1
Bach, A1
Goodman, P1
Paul, AR1
Comis, RL1
Schneider, A1
Sawyer, RC1
Derby, S1
Salvia, B1
Chiuten, DF2
Valdivieso, M2
Bedikian, A2
Bodey, GP2
Freireich, EJ2
Miller, A1
Loo, TL1
Benvenuto, JA1

Reviews

2 reviews available for phosphonoacetic acid and Adenocarcinoma, Basal Cell

ArticleYear
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 1995, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1995
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Fall, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin

1996

Trials

9 trials available for phosphonoacetic acid and Adenocarcinoma, Basal Cell

ArticleYear
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res

2004
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Investigational new drugs, 1994, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran

1994
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Cancer, 1994, Oct-01, Volume: 74, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali

1994
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Cancer research, 1993, Oct-15, Volume: 53, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1993
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorour

1996
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Investigational new drugs, 1996, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil;

1996
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Cancer, 1992, Oct-01, Volume: 70, Issue:7

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

1992
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1992
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Cancer, 1991, Jan-15, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

1991

Other Studies

15 other studies available for phosphonoacetic acid and Adenocarcinoma, Basal Cell

ArticleYear
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti

1984
Phase II study of PALA and AMSA in advanced renal cell carcinoma.
    American journal of clinical oncology, 1983, Volume: 6, Issue:5

    Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; A

1983
Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Cancer treatment reports, 1982, Volume: 66, Issue:12

    Topics: Adenocarcinoma; Aspartic Acid; Drug Evaluation; Humans; Kidney Neoplasms; Neoplasm Metastasis; Organ

1982
Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Animals; Aspartic Acid; Body Weight; Deoxycytidine; Idoxuridine; Mammary Neoplasms,

1995
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 36, Issue:3

    Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols

1993
PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    International journal of radiation oncology, biology, physics, 1996, Mar-15, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartic Acid; Bromodeoxyuridine; Cell Division; DN

1996
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac

1997
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran

2001
Antiproliferative agents and differential survival between normal and cancer cells.
    Cancer research, 1978, Volume: 38, Issue:11 Pt 1

    Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm

1978
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1992
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa

1990
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Cancer research, 1989, Aug-15, Volume: 49, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid

1989
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic

1985
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    American journal of clinical oncology, 1985, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom

1985
chemdatabank.com